AVIR · Atea Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$3.96
+0.03 (+0.76%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$318.00M
Shares
80.30M
Volume · Nov 20
416.47K
Avg daily vol (3M)
289.48K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Atea Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Atea Pharmaceuticals, Inc. (AVIR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-09
Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript
Confident tone
HCV Phase III clinical success
HEV pipeline advancement
Financial position and financing
Diluted EPS
$-0.40
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Atea Pharmaceuticals, Inc. (AVIR) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-12
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call
Diluted EPS
$-0.41
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Confident tone
Phase 3 HCV pivotal trials
Hepatitis E (HEV) program / AT587
U.S. launch preparation
Diluted EPS
$-0.57
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Confident tone
Commercial launch preparation
Hepatitis C market opportunity
Phase 3 HCV program execution
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript
Confident tone
Hepatitis E pipeline expansion
Phase III CBEYOND and C FORWARD trials
Bemifovir and riluzole regimen differentiation
Diluted EPS
$-0.53
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript
Confident tone
Unmet Need and Market Opportunity
HCV Phase III Program Progress
Market Research / Prescriber Preference
Diluted EPS
$-0.44
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript
Confident tone
Phase 3 trial design and initiation
HCV market opportunity and unmet need
Phase 2 results and HCV cure rate
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Positive tone
HCV Phase III readiness
HCV unmet need and patient profile
FDA end of Phase II meeting
Diluted EPS
$-0.37
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
Confident tone
COVID-19 program (bemnifosbuvir / SUNRISE-3)
HCV combination program (bemnifosbuvir + ruzasvir)
Phase 2 HCV leading cohort results (EASL)
Diluted EPS
$-0.48
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
Confident tone
HCV Phase II / Phase III program
COVID-19 / bemnifosbuvir program
EASL data presentation
Diluted EPS
$-0.75
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
Confident tone
HCV Phase 2 combination
COVID-19 / SUNRISE-3 Phase 3
Regulatory pathway / Phase 3 design
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.40
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Atea Pharmaceuticals, Inc. (AVIR) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.34
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.43
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Atea Pharmaceuticals, Inc. (AVIR) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.10
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.38
▼ 2000% YoY
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Atea Pharmaceuticals, Inc. (AVIR) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.51
▼ 250% YoY
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcript
Revenue
$192.18M*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Atea Pharmaceuticals, Inc. (AVIR) Q3 2021 Earnings Call Transcript
Revenue
$32.81M
Diluted EPS
$-0.34
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Atea Pharmaceuticals, Inc. (AVIR) Q2 2021 Earnings Call Transcript
Revenue
$60.39M
Diluted EPS
$0.02
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Atea Pharmaceuticals, Inc. (AVIR) Q1 2021 Earnings Call Transcript
Revenue
$65.98M
Diluted EPS
$0.34
Audio
Transcript
Slides
8-K10-Q
Showing 1–23 of 23 webcasts
Key facts
CIK
1593899
CUSIP
04683R106
13F (30d)
135 filings
118 filers
Visit website
Investor relations